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Previous studies [(1987) Biochem. J. 241, 71 l-7201 have shown that position 150 of human Clr is occupied 
by a modified amino acid that, after acid hydrolysis, yields erythro+hydroxyaspartic acid. In view of fur- 
ther investigations on the nature of this residue, peptide CNla T8/T9 TL8 (positions 147-155) was isolated 
from Cir A chain by CNBr cleavage followed by enzymatic cleavages by trypsin and thennolysin. Amino 
acid analysis, sequential Edman degradation and FAB-MS of this peptide indicate that the residue at posi- 
tion 150 is an erythro-fl-hydroxyasparagine resulting from post-translational hydroxylation of asparagine. 
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1. INTRODUCTION 
The first component of the classical pathway of 
complement, Cl, is a complex protease comprising 
a recognition unit, Clq, and Cls-Clr-Clr-Cls, a 
Ca2+-dependent tetrameric association of two 
serine proteases, Clr and Cls, which are sequen- 
tially activated through limited proteolysis during 
Cl activation [ 1,2]. The complete amino acid se- 
quence of C lr, the protease responsible for Cl 
self-activation, has been determined by protein 
[3,4] and cDNA sequencing [5,6]. The proenzyme 
is a single-chain glycoprotein (688 residues), which 
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upon activation is split, through cleavage of a 
single Arg-Ile bond [7] into two disulphide-linked 
chains, A (N-terminal) and B (C-terminal). The B 
chain (242 residues) contains the active site serine, 
whereas the A chain (446 residues) is divided into 
five structural units [4,5,8], including two pairs of 
internal repeats and one EGF-like domain. Recent 
studies have shown that residue 150 of Cir A 
chain, which is located in the EGF-like domain, is 
coded as asparagine [5,6] whereas, after acid 
hydrolysis of the corresponding peptides, it yields 
erythro-,&hydroxyaspartic acid [4]. With a view to 
further’investigations on the nature of this amino 
acid, a nonapeptide (positions 147-155) was 
isolated from Cir A chain and analyzed by sequen- 
tial Edman degradation and FAB-MS. 
2. MATERIALS AND METHODS 
2.1. Materials 
Iodo-[Z3H]acetic acid (106 mCi/mmol) was 
from Amersham. Trypsin (treated with l-chloro- 
4-phenyl-3-L-tosyl amidobutan-2-one) and ther- 
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molysin (protease type X) were obtained from 
Worthington and Sigma, respectively. eryfhro-,&- 
Hydroxyaspartic acid was made starting from 
fumaric acid according to Okai et al. [9], and fur- 
ther derivatized to erythro-/3-hydroxyasparagine 
following the procedure described by Singerman 
and Liwschitz [lo]. 
2.2. Tryptic cleavage of peptide CNla 
Purification of Cir from pooled human plasma, 
reduction of Cir, alkylation by iodo-[2-3H]acetic 
acid and separation of Cir A and B chains by high- 
pressure gel-permeation chromatography were per- 
formed as described in [ll ,121. Reduced and S- 
[3H]carboxymethylated Clr A chain was cleaved 
by CNBr and the CNBr-cleavage peptide CNla 
(positions 113-351) was purified as in [4]. CNla 
(200 nmol) was incubated in 0.1 M NHdHCO3 
with trypsin (75 pg) for 2 h at 37”C, and the in- 
cubation was repeated after addition of another 
75 pg of enzyme. Peptides CNlaT8 and CNlaT9 
(positions 13% 169) were purified by successive 
fractionation of the tryptic digest by reversed- 
phase HPLC on a pBondapak Cl8 column using 
solvent systems 1 and 2 described in [13]. 
2.3. Cleavage of tryptic peptides CNlaT8 and 
CNlaT9 by thermolysin 
Peptides CNlaTS (38 nmol) and CNlaT9 
(15 nmol) were incubated in 0.1 M NI&HCOs with 
thermolysin (3 and 1.2 pg, respectively) for 2 h at 
37”C, and each incubation was repeated after ad- 
dition of the same amounts of thermolysin. Each 
digest was fractionated by reversed-phase HPLC 
on a PBondapak Cl8 column using solvent system 
1 described in [13]. 
2.4. Amino acid analysis and sequence 
determination 
Amino acid analyses were performed on acid 
hydrolysates with a Beckman 7300 amino acid 
analyser using ninhydrin for detection. Automated 
Edman degradation of the peptides was performed 
as in [4]. 
2.5. Mass spectrometry 
Spectra were obtained on a VG Analytical ZAB- 
SE double-focusing mass spectrometer. The ac- 
celerating voltage was 10 kV and the fast xenon 
atom beam was operated with an emission current 
130 
of 0.1 mA at 8 kV. Mass spectra were recorded 
with the acquisition data system, and calibration 
was performed with CsI. Peptide CNlaT8/T9 TL8 
(10 nmol) was dissolved in 10 pl of 5% (v/v) acetic 
acid and 1 pl of this solution was added to the 
thioglycerol matrix. DADI-MIKES [14] was per- 
formed on the pseudo-molecular ion with the ac- 
quisition data system from 1000 eV to 8000 eV. A 
precision of 0.5 amu was generally obtained for 
the mass of the daughter ion. CAD-DADI-MIKES 
was obtained by addition of helium to the collision 
chamber of the second field free zone. The stream 
of helium was adjusted in order to divide the inten- 
sity of the molecular ion by a factor of three. 
3. RESULTS 
3.1. Isolation of peptides CNlaT8 and CNlaT9 
Previous sequence studies [4] have shown that 
two different amino acid residues, serine and 
leucine, occur at position 135 of human Cir. As 
expected from this heterogeneity, full tryptic 
cleavage of peptide CNla (positions 113-351) 
yielded two different peptides covering region 
135-169, both arising from cleavage of the lysyl 
bond at position 134 and of the Arg-His bond at 
position 169. These were separated by reversed- 
phase HPLC and identified by amino acid analysis 
and a short N-terminal sequence analysis. The N- 
terminal sequence of the major peptide, CNlaT8, 
was Ser-Gly-Glu-Glu-Asp-. . . , whereas that of 
CN 1 aT9 was Leu-Gly-Glu-Glu-Asp- . 
3.2. Isolation, amino acid analysis and sequence 
of peptide CNlaT81T9 TL8 
Digestion of peptides CN laT8 and CNlaT9 by 
thermolysin led to partial or complete cleavage of 
peptide bonds at position 146 (His-Leu), 151 (Tyr- 
Val), 155 (Tyr-Phe) and 164 (Glu-Leu) (see fig.2), 
in agreement with the known specificity of ther- 
molysin [ 151. Peptides generated from these 
cleavages were separated by reversed-phase HPLC 
(fig.1) and identified by amino acid analysis. In 
both cases of CNlaT8 and CNlaT9, cleavage by 
thermolysin yielded peptide CNlaT8/T9 TL8, 
resulting from cleavage of peptide bonds at posi- 
tions 146 and 155 (figs 1 and 2). Amino acid 
analysis of an acid hydrolysate of this peptide in- 
dicated the presence of erythro-,&hydroxyaspartic 
acid (table l), estimated as 0.9 mol/mol of pep- 
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Fig.1. Separation by reversed-phase HPLC of peptides 
from the digests of CNlaT8 (a) and CNlaT9 (b) by 
thermolysin. Each digest was dissolved in 0.1% (v/v) 
NHdHCO3 and separated on a pBondapak Cl8 column 
using solvent system 1 as described in [l 11. 
tide, thus confirming previous analyses of peptides 
&T3b (positions 133-169) and CNlaSP4 (posi- 
tions 129-164) [4]. N-terminal sequence analysis 
was performed on 1.0 nmol of peptide 
CNlaTWT9 TL8 and the sequence Leu-Cmc-His- 
(OH-Asn)-Tyr-Val-Gly- was obtained. The ten- 
tative assignment of the ,&hydroxyasparagine was 
made on the basis of comparable retention times 
on HPLC of the phenylthiohydantoin-derivative 
with that of a synthetic standard. 
Cleavage of CNlaT9 by thermolysin yielded a 
minor peptide, CNlaT9 TL4, resulting from par- 
tial cleavage of the Tyr-Val bond at position 151 
(figs 1 and 2). Amino acid analysis indicated the 
absence of erythro-&hydroxyaspartic acid, and the 
presence of 2 Asx residues (table 1). This result was 
confirmed by N-terminal sequence analysis of 
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F&.2. Diagrammatic representation of the major 
fragments generated by digestion of peptides CNlaT8 
(upper part) and CNlaT9 (lower part) by thermolysin. 
Fragments are numbered according to their elution 
position on HPLC (see fig. 1). Numbering of amino acid 
residues refers to their position in the sequence of Clr. 
CNlaT9 TL4, which allowed unambiguous iden- 
tification of amino acid residue 150 as asparagine. 
3.3. Analysis of CNlaT8/T9 TL8 by mass 
spectrometry 
FAB-MS is now a well established method for 
molecular mass measurement of peptides. The 
FAB-mass spectrum of peptide CNlaTWT9 TL8 
showed a large peak at m/z = 1099.4 (fig.3). Such 
a peak is usually interpreted as a pseudo-molecular 
peak corresponding to a protonated (MH+) or 
cationised (MNa+) form of the peptide. It could 
also be interpreted as a molecular ion if the peptide 
is already ionised [16]. As shown in table 2, these 
different hypotheses lead to the following 
molecular masses for peptide CNlaTWT9 TL8: 
1098.4, 1076.4 and 1099.4 Da. The eight amino 
acids unambiguously identified from Edman 
degradation and amino acid analysis of peptide 
CNlaT8/T9 TL8 correspond to a total mass of 
968.4 amu. The three possible mass values for 
amino acid at position 150 are given in table 2. 
Among these values, the only one which is consis- 
tent with the amino acid analysis is 130.0 (hydrox- 
yasparagine), which corresponds to a mass of 
1098.4 for the whole peptide. A hydroxyaspartic 
acid residue would give a pseudo-molecular ion of 
m/z = 1100.4 (MH+). Sequence analysis was per- 
formed by DADI-MIKES on the MH+ ion of pep- 
tide CNlaT8/T9 TL8 (fig.4). Sequences from both 
the N- and C-terminal ends could be interpreted 
from the spectrum: an N-terminal sequence Leu- 
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Table 1 
Amino acid compositions of selected peptides covering position 150 of 
human Clra ’ 
Amino Residues/mol 
acid 
Peptide: CNlaT8 CNlaT8/T9 TL8 CNlaT9 TL4 
Position in 
sequence: 135-169 147-155 135-151 
&OH-Asx NDC (1) 0.9 (1) - 
Asx 2.1 (2) _ 2.2 (2) 
Thr _ - - 
Ser 1.6 (2) - _ 
Glx 7.8 (8) - 4.4 (5) 
Pro 2.5 (3) - ND’ (2) 
ClY 3.7 (4) 2.3 (2) 1.0 (1) 
Ala - - - 
Val 1.0 (1) 1.0 (1) - 
1 /2Cysb 4.6d (4) 0.8 (1) 2.2 (2) 
Be - - - 
Leu 2.0 (2) 1.0 (1) 2.1 (2) 
Tyr 2.9 (3) 1.8 (2) 1.0 (1) 
Phe 1.0 (1) _ _ 
His 2.0 (2) 0.8 (1) 2.0 (2) 
LYS .- - - 
Arg 2.0 (2) _ - 
a Figures in brackets are obtained from sequence 
b Estimated as S-(carboxymethyl)cysteine 
’ Not determined 
d The overestimate is due to /?-OH-Asx, not resolved 
from S-(carboxymethyl)cysteine 
Fig.3. FAB-mass spectrum of peptide CNlaT8/T9 TL8. 
Cmc-, and a C-terminal sequence -Val-Gly-Gly- 
Tyr were clearly visible. On enlarged spectra with 
CAD, the loss of a His residue from an N-terminal 
ion (m/z = 688) and the loss of a Tyr residue from 
a C-terminal ion (m/z = 542) were visible. The se- 
quence which can be deduced from the DADI- 
MIKES studies is therefore: 
Fig.4. DADI-MIKES analysis of the pseudo-molecular 
ion (MH*) of peptide CNlaT8/T9 TL8. (a) 
Diagrammatic representation of the fragment ions 
observed in the analysis. (b) DADI-MIKES analysis. 
Peaks at m/z = 688 and m/z = 542 were only visible on 
Leu-Cmc-[His, OH-Asn, Tyr]-Val-Gly-Gly-Tyr enlarged spectra with CAD. 
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Table 2 
Different hypotheses for the calculation of the molecular 
mass of amino acid residue at position 150 of Clr 
Type of ion 1099.4 
M+H M+Na M 
Peptide mass (M) 1098.4 1076.4 1099.4 
Mass of unidentified 
amino acid (M- 968.4) 130.0 108.0 131.1 
4. DISCUSSION 
Amino acid analysis and Edman degradation of 
peptide CNlaT8/T9 TL8 led to the tentative iden- 
tification of residue 150 of Clr as erythro-@- 
hydroxyasparagine, in agreement with previous 
analysis of larger peptides covering this position 
[4]. Analysis by FAB-MS of peptide CNlaT8/T9 
TL8 rules out the hypothesis of a hydroxyaspartic 
acid and is compatible with the presence of a 
hydroxyasparagine. From the combination of 
these data, it can therefore be concluded that 
residue 150 of human Clr is an erythro-fl- 
hydroxyasparagine. This conclusion is consistent 
with: (i) analysis of the minor peptide CNlaT9 
TL4, which was found to contain asparagine at 
position 150; this partial lack of hydroxylation of 
the asparagine could be the result either of an in- 
complete hydroxylation of the asparagine, or of a 
slight chemical de-hydroxylation during peptide 
handling; (ii) the finding that residue 150 does not 
react with dicyclohexyl carbodiimide or l-ethyl- 
3-(3-dimethylaminopropyl)carbodiimide, two 
reactants known to be specific for acidic amino 
acids (unpublished); (iii) published sequence 
analyses of Clr cDNA [5,6], which show that 
residue 150 is coded as asparagine. 
It can therefore be concluded that the erythro-/3- 
hydroxyasparagine at position 150 of human Clr 
results from post-translational hydroxylation of an 
asparagine. So far, the only other reported case of 
a protein containing hydroxylated asparagine is 
bovine protein S [17]. This vitamin K-dependent 
protein contains 3 ,&hydroxyasparagine residues 
which, like residues 150 of human Clr [4], are all 
located in sequences homologous to the EGF 
precursor. Several cases of &hydroxyaspartic acid 
residues have also been described in a number of 
other vitamin K-dependent proteins, including 
protein C [18,19], factors VII, IX and X [20,23] 
and again, these residues all occur in EGF-like se- 
quences. A consensus sequence representing the 
structural requirements of the enzyme(s) responsi- 
ble for the hydroxylation of these aspartic acid or 
asparagine residues has recently been proposed by 
Stenflo et al. (171. It should be mentioned that the 
amino acid sequence surrounding residue 150 of 
human Clr is compatible with the proposed con- 
sensus . 
This work confirms the existence of a 
serine/leucine polymorphism at position 135 of 
Clr, as previously shown by protein [4] and cDNA 
sequence studies [5,6]. As this represents the only 
sequence heterogeneity found in whole human 
Clr, it provides a structural basis for the existence 
of the two common Clr alleles detected in human 
plasma by isoelectric focusing [24]. As Clr 
molecules containing either serine or leucine at 
position 135 are both hydroxylated at position 150, 
it can be concluded that residue 135 is not essential 
for the specific recognition of the EGF-like do- 
main of human Clr by the hydroxylating enzyme. 
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